Exhibit 99.1 Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non- Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with app ...